Masaki Ueno

Prof. Masaki Ueno

Faculty of Medicine, Kagawa University
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MUMasaki Ueno
Masaki Ueno
The blood-brain barrier (BBB) impedes the influx of intravascular compounds from the blood to the brain. The elements composing the BBB are endothelial cells, pericytes and the end-feet of astrocytes. Among them, the endothelial cell barrier line is the most critical for preventing toxic substances from entering the brain. In this review, we focus on the ultrastructural distribution of important components in the intracellular junction and cytoplasm of brain endothelial cells. The ultrastructural distribution of tight junction-specific integral membrane proteins such as occludin, junctional adhesion molecules, claudin, peripheral zonula occludens protein-1 (ZO-1), adherens junction-specific transmembrane protein cadherin, and adherens junction-associated peripheral proteins α-catenin, β-catenin, and p120 catenin is reviewed. P-glycoprotein and some other transporters recently discovered in endothelial cells prevent several compounds from entering the brain parenchyma. It is likely that the transient inhibition of P-glycoprotein by antidepressants enables other medicines to enter the brain. Vesicular transport with clathrin-mediated or adsorptive endocytosis through endothelial cells is also critical for transportation of bloodborn substances from the bloodstream to the brain. How medicines pass the BBB to reach the brain parenchyma is discussed.

26 February 2016 in Brain Tumor Pathology
Verified
Journal Article
Closed access
PDF file
MUMasaki Ueno
Masaki Ueno
YCYoichi Chiba
Yoichi Chiba
RMRyuta Murakami
Ryuta Murakami
KMKoichi Matsumoto
Koichi Matsumoto
MKMachi Kawauchi
Machi Kawauchi
RFRyuji Fujihara
Ryuji Fujihara

1 April 2010 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MUMasaki Ueno
Masaki Ueno
TNT. Nakagawa
T. Nakagawa
BWB. Wu
B. Wu
MOM. Onodera
M. Onodera
CHC.-L. Huang
C.-L. Huang
HSH. Sakamoto
H. Sakamoto
The blood-brain barrier (BBB) not only impedes the influx of intravascular substances from blood to brain, but also promotes transport of substances from blood to brain or from brain to blood through several transport systems such as carrier-mediated transport, active efflux transport, and receptor-mediated transport systems. The multidrug resistance transporter P-glycoprotein (P-gp) is an ATP-dependent efflux pump and contributes to efflux of undesirable substances such as amyloid-β (Aβ) proteins from the brain into the blood as well as many drugs such as anti-cancer drugs. The inhibition of P-gp has favorable and unfavorable effects on living bodies. P-gp deficiency at the BBB induces the increase of Aβ deposition in the brain of an Alzheimer disease mouse model. It is also known that the Aβ deposition is inversely correlated with P-gp expression in the brains of elderly non-demented humans. However, the transient inhibition of P-gp by antidepressants enables medicines such as anti-cancer drugs to enter the brain. Concerning Aβ clearance in the brain, the low-density lipoprotein receptor-related protein 1 (LRP1) is a major efflux transporter for Aβ, while the receptor for advanced glycation end products (RAGE) is a major influx transporter for Aβ across the BBB. Dysfunction of the BBB with efflux and influx transporters may contribute to the pathogenesis of some degenerative neuronal disorders. This review will focus on several transporters and discuss how medicines pass the BBB to reach the brain parenchyma.

26 November 2015 in Neuropathology
Verified
Journal Article
Open access
PDF file
MUMasaki Ueno
Masaki Ueno
YCYoichi Chiba
Yoichi Chiba
KMKoichi Matsumoto
Koichi Matsumoto
RMRyuta Murakami
Ryuta Murakami
RFRyuji Fujihara
Ryuji Fujihara
TNToshitaka Nakagawa
Toshitaka Nakagawa
New findings on flow or drainage pathways of brain interstitial fluid and cerebrospinal fluid have been made. The interstitial fluid flow has an effect on the passage of blood‐borne substances in the brain parenchyma, especially in areas near blood‐brain barrier (BBB)‐free regions. Actually, blood‐borne substances can be transferred in areas with intact BBB function, such as the hippocampus, the corpus callosum, periventricular areas, and medial portions of the amygdala, presumably through leaky vessels in the subfornical organs or the choroid plexus. Increasing evidence indicates that dysfunction of the BBB function may play a significant role in the pathogenesis of vascular dementia. Accordingly, we have examined which insults seen in patients suffering from vascular dementia have an effect on the BBB using experimental animal models exhibiting some phenotypes of vascular dementia. The BBB in the hippocampus was clearly deteriorated in Mongolian gerbils exposed to acute ischemia followed by reperfusion and also in stroke‐prone spontaneously hypertensive rats (SHRSP) showing hypertension. The BBB in the corpus callosum was clearly deteriorated in Wistar rats with permanent ligation of the bilateral common carotid arteries showing chronic hypoperfusion. The BBB in the hippocampus and the olfactory bulb was mildly deteriorated in aged senescence accelerated prone mice (SAMP8) showing cognitive dysfunction. The BBB in the hippocampus was mildly deteriorated in aged animals with hydrocephalus. Mild endothelial damage was seen in hyperglycemic db/db mice. In addition, mRNA expression of osteopontin, matrix metalloproteinase‐13 (MMP‐13), and CD36 was increased in vessels showing BBB damage in hypertensive SHRSP. As osteopontin, MMP‐13 and CD36 are known to be related to brain injury and amyloid β accumulation or clearance, BBB damage followed by increased gene expression of these molecules not only contributes to the pathogenesis of vascular dementia, but also bridges the gap between vascular dementia and Alzheimer's disease.

2 June 2020 in Neuropathology
Verified
Journal Article
Open access
PDF file
YCYoichi Chiba
Yoichi Chiba
YSYasunori Sugiyama
Yasunori Sugiyama
NNNozomu Nishi
Nozomu Nishi
WNWakako Nonaka
Wakako Nonaka
RMRyuta Murakami
Ryuta Murakami
MUMasaki Ueno
Masaki Ueno
Diabetes mellitus (DM) is now recognized as one of the risk factors for Alzheimer's disease (AD), and the disease‐modifying effects of anti‐diabetic drugs on AD have recently been attracting great attention. Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a new class of anti‐diabetic drugs targeting the SGLT2/solute carrier family 5 member 2 (SLC5A2) protein, which is known to localize exclusively in the brush border membrane of early proximal tubules in the kidney. However, recent data suggest that it is also expressed in other tissues. In the present study, we investigated the expression of SGLT2/SLC5A2 in human and mouse brains. Immunohistochemical staining of paraffin sections from autopsied human brains and C3H/He mouse brains revealed granular cytoplasmic immunoreactivity in choroid plexus epithelial cells and ependymal cells. Immunoblot analysis of the membrane fraction of mouse choroid plexus showed distinct immunoreactive bands at 70 and 26 kDa. Band patterns around 70 kDa in the membrane fraction of the choroid plexus were different from those in the kidney. Reverse transcription‐polymerase chain reaction analysis confirmed the expression of Slc5a2 mRNA in the mouse choroid plexus. Our results provide in vivo evidence that SGLT2/SLC5A2 is expressed in cells facing the cerebrospinal fluid, in addition to early proximal tubular epithelial cells. These findings suggest that SGLT2 inhibitors may have another site of action in the brain. The effects of SGLT2 inhibitors on brain function and AD progression merit further investigation to develop better treatment options for DM patients.

8 October 2015 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
KMKoichi Matsumoto
Koichi Matsumoto
YCYoichi Chiba
Yoichi Chiba
RFRyuji Fujihara
Ryuji Fujihara
HKHiroyuki Kubo
Hiroyuki Kubo
HSHaruhiko Sakamoto
Haruhiko Sakamoto
MUMasaki Ueno
Masaki Ueno